Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Boehringer Ingelheim | INDUSTRY |
| Daiichi Sankyo | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this study is to learn about the patient and provider perceptions, priorities, preferences, and willingness to use/prescribe anticoagulation as a stroke prevention therapy in patients with atrial fibrillation. Qualitative interviews will be performed with atrial fibrillation patients and providers caring for atrial fibrillation patients. The investigators want to understand the factors that influence decision-making about anticoagulation medications, and to gain insight into patients' and providers' knowledge of the risk of stroke and bleeding associated with oral anticoagulation. This feedback will help provide better education to providers caring for patients with atrial fibrillation and better care to patients with atrial fibrillation by developing tools to optimize the appropriate use of oral anticoagulation for patients with atrial fibrillation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients | Patients of consenting providers will complete a short survey and interview. | ||
| Providers | Physicians treating patients with atrial fibrillation will complete a short survey and interview. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Perceptions of using anticoagulation as a stroke prevention therapy in atrial fibrillation, as measured by survey and interview | Each telephone interview (data collection time point) will be approximately one hour | one hour |
| Measure | Description | Time Frame |
|---|---|---|
| Willingness to use anticoagulation as a stroke prevention therapy in atrial fibrillation, as measured by survey and interview | Each telephone interview (data collection time point) will be approximately one hour | one hour |
| preferences for using anticoagulation as a stroke prevention therapy in atrial fibrillation, as measured by survey and interview |
Not provided
Patient Inclusion Criteria:
Provider Inclusion Criteria:
1. physician at one of the study sites treating patients diagnosed with atrial fibrillation
Exclusion Criteria:
Not provided
Not provided
Not provided
Subjects will include 100 patients and 10 physicians, who are caring for those patients in the outpatient setting.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bradi B Granger, PhD | Duke University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Duke University Health System | Durham | North Carolina | 27710 | United States |
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Each telephone interview (data collection time point) will be approximately one hour |
| one hour |
| priorities for using anticoagulation as a stroke prevention therapy in atrial fibrillation, as measured by survey and interview | Each telephone interview (data collection time point) will be approximately one hour | one hour |
| D013568 |
| Pathological Conditions, Signs and Symptoms |